Bepranemab

Modify Date: 2024-01-02 17:44:31

Bepranemab structure	Common Name	Bepranemab
	CAS Number	2244960-75-4	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Bepranemab

Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research[1].

Name	Bepranemab

Description	Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research[1].
Related Catalog	Research Areas >> Neurological Disease
References	[1]. Matthew E Barton, et al. Design of a patient- and investigator-blind, randomized, placebo-controlled study to evaluate efficacy, safety, and tolerability of bepranemab, UCB0107, in prodromal to mild Alzheimer’s disease: The TOGETHER Study, AH0003. Alzheimer's & Dementia. 31 December 2021.

No Any Chemical & Physical Properties

Bepranemab

Use of Bepranemab

Names

Bepranemab Biological Activity

Chemical & Physical Properties